Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;11(8):1745-1755.
doi: 10.1007/s13300-020-00857-3. Epub 2020 Jun 19.

Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis

Peng Men  1   2 , Shuli Qu  3 , Zhenqiang Song  4 , Yanjun Liu  3 , Chaoyun Li  5 , Suodi Zhai  6   7
Affiliations

Lixisenatide for Type 2 Diabetes Mellitus Patients Inadequately Controlled on Oral Antidiabetic Drugs: A Mixed-Treatment Comparison Meta-analysis and Cost-Utility Analysis

Peng Men et al. Diabetes Ther. 2020 Aug.

Abstract

Introduction: The aim of this study was to compare the efficacy, safety and cost-utility (from the Chinese health insurance perspective) of lixisenatide and insulin regimens in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drugs (OADs).

Methods: A comprehensive literature search of English (PubMed and Cochrane Library) and Chinese (CNKI and WanFang) language databases was performed, and head-to-head relevant randomized controlled trials (RCTs) were retrieved and analyzed by performing a mixed-treatment comparison (MTC) meta-analysis for efficacy and safety endpoints. A cost-utility analysis was then conducted using the IQVIA CORE Diabetes Model to compare the lifetime pharmacoeconomic profiles among the treatment groups.

Results: Eleven RCTs were included in this MTC meta-analysis. Regarding glycated hemoglobin targets, lixisenatide was similar to both basal insulin (mean difference [MD] 0.27%; 95% credible interval [CrI] 0.02%, 0.57%) and premixed insulin (MD 0.32%; 95% CrI - 0.01%, 0.66%), respectively. Statistically significant differences were found for changes in body weight in favor of lixisenatide compared with basal insulin (MD - 3.22 kg; 95% CrI - 5.51 kg, - 0.94 kg) and premixed insulin (MD - 2.68 kg; 95% CrI - 5.16 kg, - 0.20 kg). The relative risk (RR) of symptomatic hypoglycemia associated with lixisenatide was also significantly lower than that associated with basal insulin (RR 0.22; 95% CrI 0.09, 0.52) and premixed insulin (RR 0.17; 95% CrI 0.07, 0.41). The cost-utility analysis yielded results of ¥61,072 ($8565, vs. basal insulin) and ¥127,169 ($17,836, vs. premixed insulin) per quality-adjusted life year gained, with both values falling within the willingness-to-pay threshold in China.

Conclusions: For T2DM patients inadequately controlled on OADs, lixisenatide was shown to be comparable to basal insulin and premixed insulin in terms of HbA1c and better than both of the latter in terms of both body weight loss and hypoglycemia. Lixisenatide was also a cost-effective treatment option from the perspective of Chinese health insurance.

Keywords: Chinese; Economics; GLP-1 analogue; Network meta-analysis; Type 2 diabetes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Evidence network of the mixed-treatment comparison. First author and year of publication are shown
Fig. 2
Fig. 2
Summary plots of the mixed-treatment comparison results. CrI Credible interval, FPG Fasting plasma glucose, HbA1c hemoglobin A1c (glycated hemoglobin), Lixi lixisenatide, MD mean difference, RR risk ratio
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. International Diabetes Federation . IDF diabetes atlas. 8. Brussels: International Diabetes Federation; 2017. - PubMed
    1. Pan CY, Han P, Liu X, et al. Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia) Diabetes Metab Res Rev. 2014;30(8):726–735. - PubMed
    1. Tong PC, Ko GT, So W-Y, et al. Use of anti-diabetic drugs and glycaemic control in type 2 diabetes—the Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2008;82(3):346–352. - PubMed
    1. Diabetes Society of Chinese Medical Association Guidelines for the prevention and treatment of type 2 diabetes in China (2017 edition) Chin J Diabetes. 2018;10(1):4–67.
    1. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525–536. - PubMed

LinkOut - more resources